Inebilizumab
Records for this ingredient, by country (identity only).
ATC L04AG10 · 8 markets · 8 records
US 1 records · 1 shown of 1
- 10 mg per mL / per unit basis not statedinjectionUPLIZNA
CA 1 records · 1 shown of 1
- 10 mg per mL / per unit basis not statedliquidUPLIZNA
AU 1 records · 1 shown of 1
- 100 mg per mL / per unit basis not statedinjectionUPLIZNA inebilizumab 100 mg/10 mL concentrated injection vial
ES 1 records · 1 shown of 1
- 10 mg/1 mLinjectionUPLIZNA
TW 1 records · 1 shown of 1
- 100 mg per mL / per unit basis not statedinjectionUPLIZNA for Intravenous Infusion 100 mg優視納點滴靜脈注射液100毫克
JP 1 records · 1 shown of 1
- 100 mg/10 mLinjectionユプリズナ点滴静注100mg
EU 1 records · 0 shown of 0
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
1 records · 0 manufacturers 1 registros · 0 fabricantes 1 个记录 · 0 个厂家 1 個記錄 · 0 個廠商
With a brand name Con nombre comercial 有商品名 有商品名UPLIZNA ×2
Full list in the data package Lista completa en el paquete de datos 完整清单见数据包 完整清單見資料包
FR 1 records · 1 shown of 1
- 100 mg/10 mLinjectionUPLIZNA 100 mg, solution à diluer pour perfusion
Some strengths are recorded without a per mL / per unit basis. They are shown as recorded and are not compared with other markets.
The same ingredient can carry completely different
brand names in different countries, and the same name can point to a different ingredient.
Listed by country — not interchangeable.
Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.
A side-by-side table is offered only when this ingredient has records in many markets; otherwise this list is the whole picture.